JP2023534847A5 - - Google Patents
Info
- Publication number
- JP2023534847A5 JP2023534847A5 JP2023504420A JP2023504420A JP2023534847A5 JP 2023534847 A5 JP2023534847 A5 JP 2023534847A5 JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023504420 A JP2023504420 A JP 2023504420A JP 2023534847 A5 JP2023534847 A5 JP 2023534847A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- fusion protein
- cdrs
- cytokine
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063054208P | 2020-07-20 | 2020-07-20 | |
| US63/054,208 | 2020-07-20 | ||
| PCT/US2020/062907 WO2022019945A1 (en) | 2020-07-20 | 2020-12-02 | Dual cytokine fusion proteins comprising il-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023534847A JP2023534847A (ja) | 2023-08-14 |
| JP2023534847A5 true JP2023534847A5 (cg-RX-API-DMAC7.html) | 2023-12-11 |
Family
ID=79291996
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023504420A Pending JP2023534847A (ja) | 2020-07-20 | 2020-12-02 | Il-10を含む二重サイトカイン融合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (19) | US11292822B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4181957A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023534847A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230096959A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322785A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020459746A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001187A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186753A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300062A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023000948A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022019945A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7641912B2 (ja) | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Il13を含む融合タンパク質 |
| CN116322785A (zh) * | 2020-07-20 | 2023-06-23 | 德卡生物科学公司 | 包含il-10的双细胞因子融合蛋白 |
| JP2024546999A (ja) * | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ, インコーポレイテッド | Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー |
| AU2023225954A1 (en) * | 2022-02-22 | 2024-09-05 | Deka Biosciences, Inc. | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins |
| IL328577A (en) * | 2023-11-24 | 2026-07-01 | Medpacto Inc | Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use |
| CN122555725A (zh) * | 2024-01-08 | 2026-08-11 | 上药生物治疗(香港)有限公司 | 膜表达il-10及其用途 |
| CN119954974B (zh) * | 2025-04-09 | 2025-07-22 | 四川康德赛医疗科技有限公司 | 一种工程化巨噬细胞,其制备方法及抗纤维化的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989867A (en) | 1996-09-23 | 1999-11-23 | Knappe; Andrea | DNA encoding IL-10-like homologue; related reagents |
| WO2001010912A1 (en) * | 1999-08-09 | 2001-02-15 | Lexigen Pharmaceuticals Corp. | Multiple cytokine-antibody complexes |
| WO2004021861A2 (en) * | 2002-09-03 | 2004-03-18 | Vit Lauermann | Targeted release |
| JP2009536170A (ja) | 2006-05-08 | 2009-10-08 | フィロジェン・エッセペア | 治療用の抗体標的指向サイトカイン |
| WO2008130382A2 (en) | 2006-10-31 | 2008-10-30 | East Carolina University | Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders |
| ES2536772T3 (es) | 2007-09-21 | 2015-05-28 | The Regents Of The University Of California | El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales |
| EP2209805B1 (en) | 2007-10-30 | 2017-09-06 | Philogen S.p.A. | An antigen associated with rheumatoid arthritis |
| AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
| JP2013534813A (ja) * | 2010-05-26 | 2013-09-09 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 抗cd133抗体一本鎖可変断片、及びこれらの使用 |
| WO2012045334A1 (en) | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| ES2872964T3 (es) | 2011-07-27 | 2021-11-03 | Philogen Spa | Inmunoconjugado de IL-12 |
| CN104245719B (zh) | 2011-12-12 | 2016-09-14 | 宾夕法尼亚大学托管会 | 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法 |
| US20150038678A1 (en) | 2012-02-29 | 2015-02-05 | Ambrx, Inc. | Interleukin-10 Polypeptide Conjugates and Their Uses |
| US9346872B2 (en) * | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| EP2903629B1 (en) * | 2012-10-03 | 2019-07-10 | Philogen S.p.A. | Antibody conjugate for use in treating inflammatory bowel disease |
| WO2014153056A2 (en) | 2013-03-14 | 2014-09-25 | Parkash Gill | Cancer treatment using antibodies that bing cell surface grp78 |
| JP2016519111A (ja) | 2013-04-26 | 2016-06-30 | フィロゲン エスピーエー | 細胞外マトリックス成分に対する抗体にコンジュゲートしたil4 |
| BR112016016658A2 (pt) | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| KR101811050B1 (ko) | 2015-09-02 | 2017-12-21 | 경북대학교 산학협력단 | 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물 |
| WO2017091611A1 (en) | 2015-11-23 | 2017-06-01 | Immungene, Inc | Enhanced cancer immunotherapy using antibody-interferon fusion molecules |
| US10144768B2 (en) | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
| CN106349393B (zh) * | 2015-12-21 | 2020-10-30 | 合肥立方制药股份有限公司 | 一种增强抗体药物稳定性的结构 |
| WO2017178562A1 (en) | 2016-04-12 | 2017-10-19 | Philogen S.P.A. | Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018156791A1 (en) | 2017-02-22 | 2018-08-30 | Aleta Biotherapeutics Inc. | Compositions and methods for tumor transduction |
| WO2018213335A1 (en) * | 2017-05-16 | 2018-11-22 | Scalmibio, Inc. | Activatable antibodies and methods of use thereof |
| WO2019201866A1 (en) * | 2018-04-16 | 2019-10-24 | Swedish Orphan Biovitrum Ab (Publ) | Fusion protein |
| WO2019222296A1 (en) | 2018-05-14 | 2019-11-21 | Werewolf Therapeutics, Inc. | Activatable interleukin 12 polypeptides and methods of use thereof |
| CN114072164A (zh) * | 2019-03-06 | 2022-02-18 | 德卡生物科学公司 | Il-10变体分子和治疗炎性疾病和肿瘤的方法 |
| EP4087947A4 (en) * | 2020-01-09 | 2024-05-01 | Deka Biosciences, Inc. | METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT |
| CN115867275A (zh) | 2020-04-13 | 2023-03-28 | 大学健康网络 | 治疗细胞因子释放综合征的方法 |
| CN116322785A (zh) | 2020-07-20 | 2023-06-23 | 德卡生物科学公司 | 包含il-10的双细胞因子融合蛋白 |
| KR20240007204A (ko) | 2021-05-11 | 2024-01-16 | 싱가포르 헬스 서비시즈 피티이 엘티디 | 키메라 항원 수용체 및 이를 포함하는 변형된 세포 |
| KR20240156653A (ko) | 2021-12-13 | 2024-10-30 | 데카 바이오사이언시즈, 인크. | 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질 |
| JP2024546999A (ja) | 2021-12-16 | 2024-12-26 | デカ バイオサイエンシーズ, インコーポレイテッド | Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー |
| AU2023225954A1 (en) | 2022-02-22 | 2024-09-05 | Deka Biosciences, Inc. | Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins |
-
2020
- 2020-12-02 CN CN202080105253.9A patent/CN116322785A/zh active Pending
- 2020-12-02 AU AU2020459746A patent/AU2020459746A1/en active Pending
- 2020-12-02 WO PCT/US2020/062907 patent/WO2022019945A1/en not_active Ceased
- 2020-12-02 KR KR1020237005848A patent/KR20230096959A/ko not_active Ceased
- 2020-12-02 BR BR112023001187A patent/BR112023001187A2/pt unknown
- 2020-12-02 CA CA3186753A patent/CA3186753A1/en active Pending
- 2020-12-02 IL IL300062A patent/IL300062A/en unknown
- 2020-12-02 MX MX2023000948A patent/MX2023000948A/es unknown
- 2020-12-02 JP JP2023504420A patent/JP2023534847A/ja active Pending
- 2020-12-02 EP EP20946024.5A patent/EP4181957A4/en active Pending
-
2021
- 2021-03-11 US US17/199,239 patent/US11292822B2/en active Active
-
2022
- 2022-03-01 US US17/684,243 patent/US11629178B2/en active Active
- 2022-03-01 US US17/684,205 patent/US11608368B2/en active Active
- 2022-03-01 US US17/684,229 patent/US12268903B2/en active Active
- 2022-03-01 US US17/684,272 patent/US11618775B2/en active Active
- 2022-03-01 US US17/684,106 patent/US11572397B2/en active Active
- 2022-03-01 US US17/684,151 patent/US11613563B2/en active Active
- 2022-03-01 US US17/684,290 patent/US12263358B2/en active Active
-
2023
- 2023-11-03 US US18/501,856 patent/US12116391B2/en active Active
- 2023-11-03 US US18/501,741 patent/US12121755B2/en active Active
- 2023-11-03 US US18/501,571 patent/US12145007B2/en active Active
- 2023-11-03 US US18/501,762 patent/US12006346B2/en active Active
- 2023-11-03 US US18/501,584 patent/US12122814B2/en active Active
- 2023-11-03 US US18/501,561 patent/US12116389B2/en active Active
- 2023-11-03 US US18/501,581 patent/US12110317B2/en active Active
- 2023-11-03 US US18/501,914 patent/US12116393B2/en active Active
- 2023-11-03 US US18/501,850 patent/US12116390B2/en active Active
- 2023-11-03 US US18/501,884 patent/US12116392B2/en active Active
-
2024
- 2024-10-08 US US18/909,739 patent/US20250135241A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300062A (en) | Dual fused cytokine proteins containing IL-10 | |
| JP2024546938A5 (cg-RX-API-DMAC7.html) | ||
| JP2022524018A5 (cg-RX-API-DMAC7.html) | ||
| Strohl et al. | Bispecific T-cell redirection versus chimeric antigen receptor (CAR)-T cells as approaches to kill cancer cells | |
| US20210061925A1 (en) | Trispecific and/or trivalent binding proteins | |
| Dimitrov et al. | Therapeutic antibodies: current state and future trends–is a paradigm change coming soon? | |
| Nelson | Antibody fragments: hope and hype | |
| CN105777906B (zh) | 抗pd-l1全人抗体及其应用 | |
| JP2023513003A5 (cg-RX-API-DMAC7.html) | ||
| Lu et al. | Technological advancements in antibody-based therapeutics for treatment of diseases | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| JP2021516975A5 (cg-RX-API-DMAC7.html) | ||
| JP2021516974A5 (cg-RX-API-DMAC7.html) | ||
| JP2021516976A5 (cg-RX-API-DMAC7.html) | ||
| Teillaud | From whole monoclonal antibodies to single domain antibodies: think small | |
| JP2021515566A5 (cg-RX-API-DMAC7.html) | ||
| IL313525A (en) | Dual cytokine fusion proteins containing multisubunit cytokines | |
| Roselli et al. | CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms: E. Roselli et al. | |
| RU2007145419A (ru) | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами | |
| JP2022551836A (ja) | Bcmaを標的とする抗体、二重特異性抗体及びその用途 | |
| Asano et al. | Domain order of a bispecific diabody dramatically enhances its antitumor activity beyond structural format conversion: the case of the hEx3 diabody | |
| Sadeghalvad et al. | Introduction on monoclonal antibodies | |
| JP2024546999A5 (cg-RX-API-DMAC7.html) | ||
| JP2025508882A5 (cg-RX-API-DMAC7.html) | ||
| US20220119553A1 (en) | Trispecific and/or trivalent binding proteins |